Little Is Known About MSA. We Want to Change That.

There is no cure for MSA, and there are currently no treatments available to delay the progress of the neurodegeneration it causes in the brain. There are no known genetic risk factors or early biological markers of the disease, and the typical timeframe from diagnosis to death is less than 10 years.

Research is critical for this rare and devastating disorder to offer hope to MSA patients and their families. We believe that the research we fund will help not only MSA patients, but patients with other neurological disorders such as Parkinson’s, Alzheimer’s and Dementia as well.

U

Cutting Edge Research

The Translational Genomics Research Institute (TGen) is a leader in the field of genomics – the study of a complete set of DNA.

They have demonstrated success with whole genome sequencing on patients and families with rare disorders. TGen focuses on helping patients through cutting edge translational research.

Global Effort

While MSA remains largely a mystery, there is a global effort already underway to try and understand this terrible disease.

Groundbreaking Approaches

The goal is to identify genes associated with the disease by studying MSA at the DNA-level.

TGen’s international registry allows for whole genome sequencing on those suffering from MSA as well as their families. We hope this study helps isolate genetic changes that may be causing or associated with MSA.

Shared Resources

A “Global MSA Taskforce” has been assembled to connect scientists from around the world. They will share resources and techniques for research and new therapy development.

l

Invaluable Information

Through this research, groundbreaking tactics to combat MSA could be developed, such as:

  • New ways to diagnose early-stage MSA
  • Individualized treatments that could immediately benefit MSA patients
  • Methods to calculate one’s risk of MSA before the onset of symptoms
  • New prevention approaches and techniques

Research Roadmap

Recently, researchers from 12 countries and 30 academic institutions gathered to develop a “Research Roadmap” to help guide research and treatment advancement in MSA.

Critical Findings

MSA has been found to share important development characteristics with Alzheimer’s, Parkinson’s, and other more widespread neurodegenerative diseases. MSA research could also be applied to better understanding and treating these diseases.

 

 

Why We Need Research

Within 7-10 years of diagnosis, many individuals lose their battle with MSA.

 

Critical Findings

The abnormal molecule at the core of MSA, synuclein, is becoming better understood due to recent research.

 

 

Why We Need Research

Assistance with daily activities can be required as early as 5 years after diagnosis.

 

 

Critical Findings

Brain imaging advancements hold promise to improving the diagnosis of MSA, both earlier and more accurately.

 

 

Why We Need Research

There are ZERO treatments to slow disease progression.

 

 

Critical Findings

94% of all donations since inception and 97% last year have gone directly toward funding research.

 

 

Critical Findings

MSA has been found to share important development characteristics with Alzheimer’s, Parkinson’s, and other more widespread neurodegenerative diseases. MSA research could also be applied to better understanding and treating these diseases.

 

 

Why We Need Research

Within 7-10 years of diagnosis, many individuals lose their battle with MSA.

 

Critical Findings

The abnormal molecule at the core of MSA, synuclein, is becoming better understood due to recent research.

 

 

Why We Need Research

Assistance with daily activities can be required as early as 5 years after diagnosis.

 

 

Critical Findings

Brain imaging advancements hold promise to improving the diagnosis of MSA, both earlier and more accurately.

 

 

Why We Need Research

There are ZERO treatments to slow disease progression.

 

 

Critical Findings

94% of all donations since inception and 97% last year have gone directly toward funding research.